KR880002873A - 신규의 9-디아자구아닌 - Google Patents

신규의 9-디아자구아닌 Download PDF

Info

Publication number
KR880002873A
KR880002873A KR870009320A KR870009320A KR880002873A KR 880002873 A KR880002873 A KR 880002873A KR 870009320 A KR870009320 A KR 870009320A KR 870009320 A KR870009320 A KR 870009320A KR 880002873 A KR880002873 A KR 880002873A
Authority
KR
South Korea
Prior art keywords
compound
formula
pyrrolo
pyrimidin
diamino
Prior art date
Application number
KR870009320A
Other languages
English (en)
Other versions
KR940008421B1 (ko
Inventor
로즈 코스트란 캐더린
샨드라 씨르카 자가디쉬
Original Assignee
크리스틴 에이·트라우트 웨인
워너 람버트 컴퍼니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 크리스틴 에이·트라우트 웨인, 워너 람버트 컴퍼니 filed Critical 크리스틴 에이·트라우트 웨인
Publication of KR880002873A publication Critical patent/KR880002873A/ko
Priority to KR1019940012787A priority Critical patent/KR940008848B1/ko
Application granted granted Critical
Publication of KR940008421B1 publication Critical patent/KR940008421B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Luminescent Compositions (AREA)

Abstract

내용 없음

Description

신규의 9-디아자구아닌
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (22)

  1. 일반식 I의 화합물 또는 제약학적으로 허용가능한 산 부가염 또는 염기 부가염.
    식중, R6는 OH 또는 SH ; R2는 수소 또는 NH2; R8는 수소 또는 NH2: n은 0-4중의 정수, Ar은 (i) 페닐 비치환된 또는 할로겐으로 치환된 C1-4알킬, 하이드록시, C1-4알콕시 또는 트리플루오로메틸 ; (ⅱ)2-또는 3-티에틸 ; (ⅲ) 2- 또는 3-푸란일.
  2. 제1항에 있어서, n이 1인 화합물.
  3. 제1항에 있어서, R6가 SH인 화합물.
  4. 제1항에 있어서, R6가 OH인 화합물.
  5. 제3항에 있어서, R2및 R8이 NH2인 화합물.
  6. 제4항에 있어서, R2및 R8이 NH2인 화합물.
  7. 제6항의 2,6-디아미노-3,5-디하이드로-7-(페닐메틸)-4H-피롤로〔3,2-d〕피리미딘-4-온 화합물
  8. 제7항의 모노하이드로클로라이드염 화합물.
  9. 제6항의 2,6-디아미노-3,5-디하이드로-7-(2-티엔일메틸)-4H-피롤로[3,2-d]피리미딘-4-온 화합물.
  10. 제9항의 모노하이드레이트하이드로클로라이드염 화합물.
  11. 제6항의 2,6-디아미노-3,5-디하이드로-7-(3-티엔일메틸)-4H-피롤로[3,2-d]-피리미딘-4-온 화합물.
  12. 제11항의 모노하이드로클로라이드염 화합물.
  13. 제11항의 유기산 부가염 또는 아미노산 부가염 화합물.
  14. 제6항의 2,6-디아미노-3,5-디하이드로-7-(2′-푸란일메틸)-4H-피롤로-[3,2-d〕피리미딘-4-온 화합물.
  15. 제6항의 2,6-디아미노-3,5-디하이드로-7-(2′-메톡시페닐메틸)-4H-피롤로[3,2-d]피리미딘-4-온 화합물
  16. 건선, 통풍, 자기면역질환 또는 이식거부를 치료하기 위한 건선, 통풍(항자기면역질환 또는 항이식거부)에 효과적인 양의 제1항의 화합물과 제약학적으로 허용가능한 담체로 구성된 제약학적 조성물.
  17. 단위 복용형태의 제1항의 화합물을 투약하는 것으로 구성된 자기면역 질환 또는 이의 거부를 치료하는 방법.
  18. 건선으로 고통받는 사람을 치료하기 위해 제1항의 화합물을 단위 복용형태로 투약하는 것으로 구성된 방법.
  19. 통풍으로 고통받는 사람을 치료하기 위해 제1항의 화합물을 단위 복용형태로 투약하는 것으로 구성된 방법.
  20. R8이 산소이고 R8이 아미노인 일반식 I의 화합물을 얻기 위하여 염기성 용액에서 Na2S2O2와 R2와 Ar이 상기한 바와 같은 일반식(II)화합물을 처리하고,
    한편 R8이 수소인 일반식 I 화합물을 얻기 위하여 촉매 존재하에 아미노를 산소로 더욱 환원시키고, 만일 원한다면 업계에 공지된 유사한 방법으로 일반식 I 화합물의 R8을 O 또는 OH에서 S 또 SH로 전환시키는 것으로 구성된 제1항의 화합물을 제조하고 만일 필요하다면 일반식 I의 화합물의 제약학적으로 허용가능한 산 부가 또는 염기 부가염을 제조하는 방법.
  21. 일반식(II)의 화합물
    식 중, R2는 수소 또는 NH2, Ar은 (i) 페닐비치환된 또는 할로겐으로 치환된 C1-4알킬, 하이드록시, C1-4알콕시 또는 트리플루오로메틸, (ⅱ) 2- 또는 3-티엔일, (ⅲ) 2- 또는 3-푸란일.
  22. 일반식(Ⅲ)의 화합물
    식 중, R2는 수소 또는 NH2, Ar은 (i) 페닐비치환된 또는 할로겐으로 치환된 C1-4알킬, 하이드록시, C1-4알콕시 또는 트리플루오로메틸, (ⅱ) 2- 또는 3-티엔일, (ⅲ) 2- 또는 3-푸란일.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019870009320A 1986-08-26 1987-08-26 신규의 9-디아자구아닌 KR940008421B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019940012787A KR940008848B1 (ko) 1986-08-26 1994-06-08 신규의 9-디아자구아닌

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US90048686A 1986-08-26 1986-08-26
US900,486 1986-08-26
US5941987A 1987-06-18 1987-06-18
US059,419 1987-06-18
US900486 1987-06-18
US59419 1987-06-18

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1019940012787A Division KR940008848B1 (ko) 1986-08-26 1994-06-08 신규의 9-디아자구아닌

Publications (2)

Publication Number Publication Date
KR880002873A true KR880002873A (ko) 1988-05-12
KR940008421B1 KR940008421B1 (ko) 1994-09-14

Family

ID=26738724

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1019870009320A KR940008421B1 (ko) 1986-08-26 1987-08-26 신규의 9-디아자구아닌
KR1019940012787A KR940008848B1 (ko) 1986-08-26 1994-06-08 신규의 9-디아자구아닌

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1019940012787A KR940008848B1 (ko) 1986-08-26 1994-06-08 신규의 9-디아자구아닌

Country Status (16)

Country Link
EP (1) EP0260491B1 (ko)
JP (2) JP2595254B2 (ko)
KR (2) KR940008421B1 (ko)
AT (1) ATE67203T1 (ko)
AU (1) AU619724B2 (ko)
CA (2) CA1293727C (ko)
DE (1) DE3772913D1 (ko)
DK (1) DK169705B1 (ko)
ES (1) ES2038635T3 (ko)
FI (1) FI85856C (ko)
GR (1) GR3002697T3 (ko)
IE (1) IE60433B1 (ko)
NO (1) NO166485C (ko)
NZ (1) NZ221463A (ko)
PH (1) PH24669A (ko)
PT (1) PT85582B (ko)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1294960C (en) * 1986-10-24 1992-01-28 Thomas C. Malone 7-deazaguanines as immunomodulators
DE69031337T2 (de) * 1989-02-27 1998-03-05 Biocryst 9-substituierte-8-unsubstituierte-9-deazaguanine
HUT61765A (en) * 1989-10-31 1993-03-01 Biocryst Inc Process for producing purine nucleoside phosphorylase inhibitors and pharmaceutical compositions comprising same as active ingredient
US5726311A (en) * 1989-11-29 1998-03-10 Biocryst Pharmaceuticals, Inc. 7-disubstituted-methyl-4-oxo-3H,5H-pyrrolo 3,2-d!pyrimidine and pharmaceutical uses and compositions containing the same
WO1995001355A1 (en) * 1993-06-30 1995-01-12 Biocryst Pharmaceuticals, Inc. 9-deazahypoxanthines as pnp inhibitors
US5386031A (en) * 1993-12-15 1995-01-31 Warner-Lambert Company Process for the synthesis of 2-amino-3,5-dihydro-7-substituted-4H-pyrrolo[3,]pyrimidin-4-ones
JPH10507171A (ja) * 1994-10-05 1998-07-14 カイロサイエンス・リミテッド Ｐｎｐインヒビターとしてのプリンおよびグアニン化合物
FR2728181B1 (fr) * 1994-12-16 1997-01-31 Appryl Snc Composante catalytique pour la polymerisation des olefines, son procede de fabrication, et procede de polymerisation des olefines en presence de ladite composante catalytique
SK72996A3 (en) * 1995-06-07 1997-04-09 Pfizer Heterocyclic ring-fused pyrimidine derivatives and pharmaceutical compositions on their base
US6395733B1 (en) 1995-06-07 2002-05-28 Pfizer Inc Heterocyclic ring-fused pyrimidine derivatives
NZ523970A (en) * 2003-02-04 2005-02-25 Ind Res Ltd Process for preparing inhibitors of nucleoside phoshorylases and nucleosidases
CA2540598C (en) * 2003-10-03 2013-09-24 3M Innovative Properties Company Pyrazolopyridines and analogs thereof
NZ540160A (en) * 2005-05-20 2008-03-28 Einstein Coll Med Inhibitors of nucleoside phosphorylases
GB201417163D0 (en) 2014-09-29 2014-11-12 Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases
GB201417165D0 (en) * 2014-09-29 2014-11-12 Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin Treatments for Autoimmune Disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN164556B (ko) * 1986-03-06 1989-04-08 Takeda Chemical Industries Ltd
CA1294960C (en) * 1986-10-24 1992-01-28 Thomas C. Malone 7-deazaguanines as immunomodulators
DE3739366A1 (de) * 1987-04-10 1988-10-27 Boehringer Mannheim Gmbh Desaza-purin-nucleosid-derivate, verfahren zu deren herstellung sowie deren verwendung bei der nucleinsaeure-sequenzierung sowie als antivirale mittel

Also Published As

Publication number Publication date
EP0260491B1 (en) 1991-09-11
NZ221463A (en) 1990-07-26
ES2038635T3 (es) 1993-08-01
GR3002697T3 (en) 1993-01-25
PH24669A (en) 1990-09-07
PT85582B (pt) 1990-05-31
EP0260491A1 (en) 1988-03-23
JP2650644B2 (ja) 1997-09-03
DE3772913D1 (de) 1991-10-17
NO873584L (no) 1988-02-29
DK440287D0 (da) 1987-08-24
FI873648A0 (fi) 1987-08-24
KR940008848B1 (ko) 1994-09-28
AU619724B2 (en) 1992-02-06
NO873584D0 (no) 1987-08-25
KR940008421B1 (ko) 1994-09-14
FI85856B (fi) 1992-02-28
PT85582A (en) 1987-09-01
IE60433B1 (en) 1994-07-13
FI873648A (fi) 1988-02-27
DK169705B1 (da) 1995-01-16
AU7741687A (en) 1988-03-03
IE872070L (en) 1988-02-26
FI85856C (fi) 1992-06-10
JPS6388185A (ja) 1988-04-19
JPH08311040A (ja) 1996-11-26
NO166485C (no) 1991-07-31
CA1320203C (en) 1993-07-13
CA1293727C (en) 1991-12-31
DK440287A (da) 1988-02-27
JP2595254B2 (ja) 1997-04-02
ATE67203T1 (de) 1991-09-15
NO166485B (no) 1991-04-22

Similar Documents

Publication Publication Date Title
KR880002873A (ko) 신규의 9-디아자구아닌
KR900001699A (ko) 7-(1-피롤리디닐)-3-퀴놀론-및-나프티리돈카르복실산 유도체, 그의 제조방법 및 그의 제조에 있어서 중간체 생성물로서 치환된 모노- 및 비시클릭 피롤리딘 유도체, 항박테리아제 및 이들을 함유하는 사료 첨가제
EA199800394A1 (ru) Пиразолпиримидины как антагонисты крф рецепторов
TR199801755T2 (xx) Pirimido(5,4-D)pirimidinler, bu bile�ikleri i�eren farmas�tik maddeler.
RU2003116648A (ru) Замещенные имидазопиридины
RU2006122853A (ru) Производные диарилмочевины для лечения заболеваний, зависимых от протеинкиназы
EA199800611A1 (ru) Производные фенилтиазола с противогерпетическими свойствами
CA2385269A1 (en) Novel thiazolo(4,5-d)pyrimidine compounds
BR9714063A (pt) Composto, processo para a preparação e uso do mesmo, composição farmacêutica, e, processos para preparação da mesma, para executar a imunossupressão e para tratar ou reduzir o risco de uma doença reversìvel, obstrutiva das vias aéreas
UA27901C2 (uk) Похідні 7-(2-аміноетил)бензотіазолону, що проявляють агоністичну активність по відношенню до бета2-адренорецепторів, фармацевтична композиція, спосіб їх отримання та проміжні сполуки
EA200301063A1 (ru) Фармацевтические агенты для лечения ганв и микроаденом
ATE242246T1 (de) (1,2,3)-triazolo(4,5-d)pyrimidin-derivate als antithrombotische mittel
KR880007538A (ko) 피리다조 디아제핀 유도체
ATE152352T1 (de) Pharmazeutische zusammensetzungen zur hemmung der maillardreaktion
ATE161725T1 (de) Verwendung von phosphatdiestern zur behandlung von erkrankungen der retina
KR920004387A (ko) 진통제 및 피부질환 치료용 국소용 소염제로서의 4-치환된 디하이드로피리도[4,3-d]피리미딘
DE3362283D1 (en) Novel derivatives of guanine
DK0626367T3 (da) (7S)-7- (2R)-2-(3-chlorphenyl)-2-hydroxyethylamino -5,6,7,8-tetrahydronapthalen-2-yloxyeddikesyre og farmaceutisk acceptable salte deraf med beta3-adrenerg agonistvirkning, farmaceutiske præparater og laboratoriereagenser som indeholder den.
NZ216334A (en) Spiro imidazolone derivatives and pharmaceutical composition
KR880006203A (ko) 융합된 헤테로사이클릭 테트라하이드로아미노 퀴놀리놀 및 관련 화합물, 이들의 제조방법 및 약제로서의 용도
DK527186D0 (da) Bronchodilaterende farmaceutisk praeparat
KR870007181A (ko) 피롤로[1,2-a] [4,1] 벤즈옥사제핀 유도체
DE3363376D1 (en) Novel derivatives of guanine
BR9808546A (pt) Composto, composição farmacêutica, uso de um composto, e, processos para tratar ou reduzir o risco de doenças ou condições do ser humano, tratar ou reduzir o risco de doença inflamatória e o risco da dor em uma pessoa que sofre, ou em risco, da dita doença e para a preparação do composto
KR910020018A (ko) 피리도[3, 4-b] 피롤로[1, 2-e][1, 4, 5]옥사디아제핀 및 이의 관련 동족체 이의 제조방법 및 약제로서의 이의 용도

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20020726

Year of fee payment: 9

LAPS Lapse due to unpaid annual fee